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Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Food Allergens (NDA) was asked to deliver an opinion on pasteurised Akkermansia muciniphila as a
novel food (NF) pursuant to Regulation (EU) 2015/2283. A. muciniphila is a well-characterised non-
toxin producing, avirulent microorganism that has been reported as part of normal gut microbiota. The
NF, pasteurised A. muciniphila, is proposed by the applicant to be used as a food supplement at max.
5 9 1010 cells/day by adults excluding pregnant and lactating women, and in foods for special medical
purposes. The Panel considers that the production process of the NF is sufficiently described and that
the information provided on the composition of the NF is sufficient for its characterisation. Taking into
account the composition of the NF and the proposed conditions of use, the consumption of the NF is
not nutritionally disadvantageous. Based on literature data, and by applying an uncertainty factor of
200 to the no observed adverse effect level (NOAEL) of a 90-day repeated dose oral toxicity study in
rats, the Panel concludes that the consumption of 3.4 9 1010 cells/day is safe for the target population
under the provision that the number of viable cells in the NF is < 10 colony forming units (CFU)/g (i.e.
limit of detection).
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
On 24 October 2019, the company A-Mansia Biotech S.A., submitted a request to the Commission
in accordance with Article 10 of Regulation (EU) No 2015/2283 to place on the EU market pasteurised
Akkermansia muciniphila as a novel food.
Pasteurised Akkermansia muciniphila is intended to be used in food supplements as defined in Directive
2002/46/EC, and in foods for special medical purposes as defined in Regulation (EU) No 609/2013.
The applicant has requested data protection according to the provisions of Article 26 of Regulation
(EU) 2015/2283.
In accordance with Article 10(3) of Regulation (EU) 2015/2283, the European Commission asks the
European Food Safety Authority to provide a scientific opinion on pasteurised Akkermansia muciniphila
as a novel food.
2. Data and methodologies
2.1. Data
The safety assessment of this NF is based on data supplied in the application, information submitted
by the applicant following two EFSA requests for supplementary information and information provided by
the EFSA BIOHAZ Panel in the context of the QPS assessment for Akkermansia muciniphila.
Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in the Commission Implementing Regulation (EU) 2017/24691.
A common and structured format on the presentation of NFapplications is described in the EFSA guidance
on the preparation and presentation of an NF application (EFSA NDA Panel, 2016). As indicated in this
guidance, it is the duty of the applicant to provide all of the available (proprietary, confidential and published)
scientific data (including both data in favour and not in favour) that are pertinent to the safety of the NF.
This NF application includes a request for protection of proprietary data in accordance with Article 26
of Regulation (EU) 2015/2283. The data requested by the applicant to be protected comprise: bacterial
reverse mutation test (Brient, 2019a, unpublished), in vitro micronucleus assay (Brient, 2019b,
unpublished), 14-day dose range-finding toxicity study (Bracken, 2019a, unpublished), 90-day toxicity
study (Bracken, 2019b, unpublished), published toxicity-data (Druart et al., 2020), flow cytometry
validation (Jensen, 2019, unpublished), antimicrobial resistance study (Gueimonde, 2019, unpublished).
2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications (EFSA NDA
Panel, 2016) and the principles described in the relevant existing guidance documents from the EFSA
Scientific Committee. The legal provisions for the assessment are laid down in Article 11 of Regulation
(EU) 2015/2283 and in Article 7 of the Commission Implementing Regulation (EU) 2017/2469.
This assessment concerns only the risks that might be associated with consumption of the NF
under the proposed conditions of use, and is not an assessment of the efficacy of the NF with regard
to any (claimed) benefit.
3. Assessment
3.1. Introduction
The NF which is the subject of the application is pasteurised Akkermansia muciniphila. The NF is
produced by anaerobic growth of the bacterium followed by pasteurisation and freeze-drying. The NF
is proposed by the applicant to be used in food supplements and in foods for special medical purposes
(as defined in Regulation (EU) No 609/2013). The proposed target population is the general adult
population excluding pregnant and lactating women.
The NF falls under Article 3(2)(a)(ii) foods consisting of, isolated from or produced from
microorganisms, fungi or algae, as defined in Regulation (EU) 2015/2283.
1 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientific
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
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3.2. Identity of the NF
The NF is pasteurised Akkermansia muciniphila MucT which is a Gram-negative, strictly anaerobic,
non-motile and non-spore-forming human gut bacterium.
The species A. muciniphila has been shown to be a mucin-degrader, i.e. it uses intestinal mucin as
source for carbon and nitrogen (Derrien et al., 2004). The mucins are high-molecular mass
glycoproteins (produced by intestinal goblet cells) which form a viscous gel, i.e. the mucus, that lines
and protects (as a barrier defence) the gastrointestinal tract.
The full taxonomic classification of the employed strain is the following; Empire: Prokaryota;
Kingdom: Bacteria; Phylum: Verrucomicrobia; Class: Verrucomicrobiae; Order: Verrucomicrobiales;
Family: Verrucomicrobiaceae; Genus: Akkermansia; Species: Akkermansia muciniphila; Strain:
Akkermansia muciniphila MucT (ATCC BAA-835T=CIP 107961T).
The strain is deposited at two culture collections, i.e. at the American Type Culture Collection
(ATCC) under accession number ATCC BAA-835T and at the Collection de l’Institut Pasteur (CIP) under
accession number CIP 107961T, for which a certificate of deposition was provided by the applicant.
The isolation of the strain MucT from human faeces and its morphological, physiological and
phylogenetic features were first described by Derrien et al. (2004). The whole genome was sequenced
by PacBio and Illumina shotgun genome sequence analysis (National Center for Biotechnology
Information (NCBI) Ref. Sequence: NC-010655.1).
The taxonomic identification of the strain MucT as A. muciniphila was additionally established by
several phylogenetic analyses using the whole genome sequence (WGS). A dendrogram using
genome-aligning software MUMmer and based on average nucleotide identity (ANI), an SNP tree
based on the core genome phylogeny and the associated SNP distance matrix showed that the MucT
strain clustered with the NCBI genome of the reference species.
3.3. Production process
According to the information provided, the NF is produced in line with good manufacturing practice
(GMP) and hazard analysis critical control points (HACCP) principles.
The process flow diagram together with a detailed description of the methods involved at each step
and a complete list of the culture media and processing aids plus the respective certificates of analysis
were provided (confidential information).
In short, an inoculum of A. muciniphila is made by successive preculture steps in liquid media in
strictly anaerobic conditions at increasing volumes in order to prepare for the inoculation of the main
fermenter. The main fermentation is conducted under strictly anaerobic conditions at a certain
temperature and pH (confidential information), while stirring. The growth of A. muciniphila is
monitored via spectrophotometry at regular time points.
The production process for pasteurised A. muciniphila consists of an anaerobic fermentation followed by
pasteurisation and concentration of the bacterial cells. The cells are then mixed with cryoprotectants and
freeze-dried in order to produce a powder. Total bacterial cell counting is performed and, if required, the
powder is mixed with stabilising agents. The applicant informed that the addition of stabilising agents is an
optional step in the manufacturing process, in order to dilute the powder at a given cell counting (i.e. the
proportion and the quantity added depends on the production yield and the quantification of the cell count in
the ‘raw’ powder). At the current production practice, the NF is standardised to 1 9 1011 cells (measured as
total fluorescent units (TFU))/g of powder.
The bulk powder is packaged into water- and airproof multi-layer pouches, heat sealed and stored
at ≤ –18°C until the powder is packed in final products which are to be stored (e.g. by wholesalers,
retailers, consumers) at 15–25°C, protected from light and moisture. The proposed shelf-life is 1 year.
The Panel considers that the production process is sufficiently described.
3.4. Compositional data
The NF, pasteurised A. muciniphila, consists of carbohydrates (~ 45%), proteins (~ 30%), ash
(~ 18%), moisture (~ 6%) and minor amounts of fat.
In order to confirm that the manufacturing process is reproducible and adequate to produce on a
commercial scale a product with certain characteristics, the applicant provided analytical information
for five independent batches of the NF (before the addition of stabilising agents) (Table 1). The
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appearance of all batches was that of an off-white to beige homogenous powder, as confirmed by
visual inspection.
The total cell count of pasteurised Akkermansia muciniphila in the batch testing was measured (as
TFU) by flow cytometry according to the ‘A-Mansia method’ (denominated as VC01_V1.0 in the
respective certificate of analysis), for which the validation report was provided.




#1 #2 #3 #4 #5
Species identification
(A. muciniphila)
Conforms Conforms Conforms Conforms Conforms 16S rRNA gene
sequencing (Sanger
Method)
A. muciniphila – total
cell count (cells (as
TFU)/g)
2.23 9 1011 1.78 9 1011 1.13 9 1011 9.34 9 1010 9.94 9 1010 Flow cytometry




< 10 < 40 400 30 20 Plating (LoQ = 10 CFU/g)
Protein (%) 31.6 26.5 30.2 29.8 32.2 Kjeldhal or Dumas
method
Fat (%) 1.2 0.6 0.5 0.5 0.2 Extraction after hydrolysis/
gravimetry
Moisture (%) 5.5 7.4 8.5 3.9 4.9 Vacuum drying method
Ash (%) 18.4 19.7 19.3 19.5 13.2 Dry ashing
Carbohydrates (%) 43.3 45.8 41.5 46.3 49.5 By calculation(1)
Water activity 0.17 0.28 0.35 0.32 0.29 NF ISO 21807:2004
Heavy metals
Arsenic (mg/kg) 0.25 0.22 0.23 0.18 0.17 ICP-MS
Cadmium (mg/kg) 0.005 0.009 0.006 0.006 0.015 ICP-MS
Mercury (mg/kg) < 0.02 < 0.02 < 0.02 < 0.02 < 0.02 ICP-MS




< 10 < 10 < 40 < 10 < 10 NF EN ISO 4833-1
Sulfite-reducing
anaerobes (CFU/g)
< 10 < 10 < 10 40 < 10 ISO 15213
Coagulase +
Staphylococci (CFU/g)
< 10 < 10 < 10 < 10 < 10 NF EN ISO 6888-2
Enterobacteriaceae
(CFU/g)
< 10 < 10 < 10 < 10 < 10 ISO 21528-2
Bacillus cereus
(CFU/g)
< 10 < 10 < 10 < 10 < 10 NF EN ISO 7932





































Yeasts (CFU/g) < 10 < 10 < 10 < 10 < 10 ISO 21527-2:2008
Moulds (CFU/g) < 10 < 10 < 10 < 10 < 10 ISO 21527-2:2008
CFU: colony forming units, ICP-MS: inductively coupled plasma mass spectrometry, ISO: International Organization for
Standardization, LoQ: limit of quantification, NF: norme francaise (French Standard), rRNA: ribosomal ribonucleic acid, TFU: total
fluorescent units.
(1): Carbohydrates% = 100% – protein% – fat% – moisture% – ash%).
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Analyses of mycotoxins and polycyclic aromatic hydrocarbons in the NF were not performed.
However, the applicant provided certificates of analysis for the raw materials, which state the absence of
these contaminants in the raw materials used for the fermentation. These certificates of analysis
confirmed also the absence of pesticide residues in the raw materials. Two batches of the NF were
nonetheless analysed for the presence of pesticides and related compounds. No residues of these
pesticides or related compounds were detected above their respective limits of quantification/detection.
The applicant also provided a particle size analysis (by laser diffraction), where 50% of the
cumulative distribution ranged between 50 and 100 lm. The smallest particle sizes detected were
between 1 and 5 lm.
Information was provided on the accreditation of the laboratories that conducted the analyses
presented in the application.
The Panel considers that the information provided on the composition of the NF is sufficient for
characterising the NF.
3.4.1. Stability
The applicant performed stability tests with three independently produced batches of the NF. The
tests were carried out at ambient (at 25°C and 60% relative humidity (RH), Table 2) and at accelerated
conditions (at 40°C and 75% RH, Table 3) for up to 12 months. The batches were analysed for total and
viable A. muciniphila cell counts and additional microbiological parameters (not shown) as per the
specifications for the NF. The analysed parameters remained within the limits as set in the specifications
as originally proposed by the applicant. A shelf-life of one year was proposed by the applicant.
Table 2: Total and viable A. muciniphila cell counts in the NF during the stability testing under
ambient conditions (25°C and 60% RH)
Parameter
Time Batch number
(months) #1 #2 #3
Total A. muciniphila cell
count (TFU (cells)/g)
0 2.23 9 1011 1.78 9 1011 1.13 9 1011
3 1.89 9 1011 1.80 9 1011 1.23 9 1011
6 1.84 9 1011 1.54 9 1011 1.32 9 1011
12 2.86 9 1011 1.41 9 1011 1.05 9 1011
Viable A. muciniphila cell
count (CFU/g)
0 < 10 10 ne 400
3 < 10 240 390
6 < 10 < 10 < 10
12 30 ne 20 ne < 10
CFU: colony forming units; ne: estimated number; TFU: total fluorescent units.
Table 3: Total and viable A. muciniphila cell counts in the NF during the stability testing under
accelerated conditions (40°C and 75% RH)
Parameter
Time Batch number
(months) #1 #2 #3
Total A. muciniphila cell
count (TFU (cells)/g)
0 2.23 9 1011 1.78 9 1011 1.13 9 1011
1 1.54 9 1011 8.11 9 1010 1.16 9 1011
3 1.19 9 1011 9.11 9 1010 9.23 9 1010
6 9.84 9 1010 1.06 9 1011 8.40 9 1010
12 2.34 9 1011 1.66 9 1011 9.47 9 1010
Viable A. muciniphila cell
count (CFU/g)
0 < 10 10 ne 400
1 < 10,0001) < 10,000(1) < 10,000(1)
3 < 10 < 10 36
6 < 10 < 10 < 10
12 < 10 30 ne < 10
CFU: colony forming units; ne: estimated number; TFU: total fluorescent units.
(1): A different less sensitive detection method was used at that time point.
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The Panel considers that the data provided sufficient information with respect to the stability of the
NF.
3.5. Specifications
The specifications of the NF are indicated in Table 4.
With respect to the parameter of viable A. muciniphila cell count, the applicant originally specified
up to 0.0001% viable cells of the overall cell count. Following a request from EFSA to lower
this parameter to < 10 CFU/g (i.e. limit of detection), the applicant proposed a specification limit of
< 500 CFU/g. The Panel notes that at the proposed conditions of use (5 9 1010 cells/day) and
considering < 500 CFU/g, the intake could be up to 1,000 viable A. muciniphila cells per day.
The Panel considers that taking into account the presence of A. muciniphila in the human gut and
the instance that infants can be exposed to A. muciniphila via the breast milk, the risk following
consumption of up to 1,000 live A. muciniphila cells per day via the NF is likely to be low. However,
at this exposure level, a possible adverse impact on the gut barrier integrity and balance of
the microbiota in susceptible people cannot be ruled out based on the available information (see
section 3.10.1). Therefore, the Panel retains that the parameter for viable A. muciniphila should be set
to < 10 CFU/g (i.e. limit of detection).
The Panel considers that the information provided on the specifications of the NF is sufficient and
does not raise safety concerns.
3.6. History of use of the NF and/or of its source
The NF does not have a history of use as or in food.
The applicant informed that the source, i.e. A. muciniphila, has been detected in human milk by
quantitative polymerase chain reaction (PCR) (Collado et al., 2012). A. muciniphila has also been
detected by quantitative PCR in colostrum by Aakko et al. (2017).
Table 4: Specifications of the NF
Description: pasteurised Akkermansia muciniphila (strain ATCC BAA-835) produced by anaerobic fermentation,
followed by pasteurisation and freeze-drying
Parameter Specification
Total A. muciniphila cell count (cells/g) 2.5 9 1010–2.5 9 1012
Viable A. muciniphila cell count (CFU/g) < 10 (LoD)(1)
Water activity ≤ 0.43
Moisture (%) ≤ 10(2)
Protein (%) 25–35(2)
Fat (%) 0–2(2)
Crude ash (%) 17–21(2)
Carbohydrates (%) 36–48(2)
Microbiological
Aerobic mesophilic total count (CFU/g) ≤ 500
Sulfite-reducing anaerobes (CFU/g) ≤ 50
Coagulase + Staphylococci (CFU/g) ≤ 10
Enterobacteriaceae (CFU/g) ≤ 10
Yeasts (CFU/g) ≤ 10
Moulds (CFU/g) ≤ 10
Bacillus cereus (CFU/g) ≤ 100
Listeria spp. Not detected in 25 g
Salmonella spp. Not detected in 25 g
Escherichia coli Not detected in 1 g
CFU: colony forming units; LoD: limit of detection.
(1): For cultivation conditions, see Van der Ark et al. (2018).
(2): The numbers given refer to the undiluted NF. The ranges for these parameters are expected to change according to the
amount of stabilising agents added.
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3.7. Proposed uses and use levels
3.7.1. Target population
The target population proposed by the applicant is the general adult population excluding pregnant
and lactating women.
3.7.2. Proposed uses and use levels
The NF is proposed by the applicant to be used in food supplements at up to 5 9 1010 TFU (i.e.
cells)/day.
At the proposed specifications for the NF (i.e. from 2.5 9 1010 to 2.5 9 1012 cells/g), the maximum
proposed dose of 5 9 1010 cells/day corresponds to 0.02–2 g of the NF.
The NF is also proposed by the applicant to be used in foods for special medical purposes as
defined by Regulation (EU) No 609/2013, with the use level to be determined on a case-by-case basis
(in any case not more than 5 9 1010 TFU per day).
3.8. Absorption, distribution, metabolism and excretion (ADME)
The applicant did not provide any ADME data for the NF. Instead, the applicant pointed out that A.
muciniphila is a common member of the human intestinal tract (Collado et al., 2007; Derrien et al.,
2008).
The Panel considers that given the nature of the NF, no ADME testing is required for the safety
assessment of the NF.
3.9. Nutritional information
The applicant provided proximate analyses for three batches of the NF, which showed that the NF
is mainly composed of carbohydrates (41–49%), protein (26–32%), ash (13–20%) and moisture (5–
9%).
For two batches of the NF, additional analyses were provided on the concentrations of a number of
minerals including trace elements.
The Panel considers that taking into account the composition of the NF and the proposed
conditions of use, consumption of the NF is not nutritionally disadvantageous.
3.10. Toxicological information
3.10.1. Microbiological information
Prevalence of A. muciniphila in human gut
In a study comprising 249 subjects across various age groups, A. muciniphila was detected in
faecal samples from 8 of 50 1-month-old infants (16%), 36 of 50 infants aged 6 months (72%), 45 of
50 children at 12 months of age (90%), 54 out of 54 in adults (100%) and 43 out of 45 in elderly
(96%). In adults, a median of about 1 9 108 A. muciniphila cells per gram faeces (as determined by
quantitative PCR) was reported (Collado et al., 2007).
According to a study by Derrien et al. (2008) performed with faecal samples, A. muciniphila
accounts for about 1–3% of naturally occurring human intestinal microbes.
In a combined analysis of large global data sets (N combined = 3,948 subjects) of faecal samples,
the genus Akkermansia was present in 77.7% of the total assessed cohorts globally and in 81.8% of
two cohorts of Western populations (Falony et al., 2016).
Qualified presumption of safety (QPS) of A. muciniphila
In 2020, the species A. muciniphila was assessed by the EFSA Panel on Biological Hazards
(BIOHAZ) for its suitability to be added to the list of qualified presumption of safety (QPS)-
recommended biological agents intentionally added to food or feed (EFSA BIOHAZ Panel, 2020). For
this purpose, the BIOHAZ Panel considered the identity, the body of knowledge, safety concerns and
antimicrobial resistance aspects of this taxonomic unit.
The BIOHAZ Panel acknowledged that A. muciniphila is abundant in the colon of humans and
animals and has also been detected in human milk samples (Collado et al., 2012). The Panel also
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stated that the prevalence of A. muciniphila appears to be decreased in gut microbiota of people
suffering from the ‘metabolic syndrome’ (including obesity, diabetes, cardiometabolic disease and low-
grade inflammation). However, the BIOHAZ Panel pointed out that the prevalence of A. muciniphila
was found to be increased in gut microbiota of people suffering from Parkinson’s disease, multiple
sclerosis, Alzheimer’s disease and autism spectrum disorders, although for autism depletion of the
microorganism was reported as well. The BIOHAZ Panel concluded that A. muciniphila cannot be
recommended for the QPS list due to safety concerns (EFSA BIOHAZ Panel, 2020).
A. muciniphila in disease
There are a number of studies available in the literature on the relationship of viable A. muciniphila
with disease. The Panel reviewed those that were identified by the EFSA BIOHAZ Panel (2020) and
also reviewed further studies which were identified by the experts of the Panel or the Working Group
on NF or were submitted by the applicant subsequently to EFSA’s requests for additional information.
The studies comprised human observational studies and animal studies (including murine models of
(neurological) diseases and experiments in gnotobiotic/germ-free mice).
The reviewed studies were concerned with Alzheimer’s disease (Vogt et al., 2017; Zhuang et al.,
2018; Ou et al., 2020), arthritis (Stoll et al., 2014, 2019; Asquith et al., 2016), autism (Finegold et al.,
2010; Wang et al., 2011; De Angelis et al., 2013; Xu et al., 2019; Zou et al., 2020), colitis/
inflammatory bowel disease (Png et al., 2010; Ganesh et al., 2013; Desai et al., 2016; Seregin et al.,
2017; Bian et al., 2019; Ring et al., 2019; Zhai et al., 2019), colorectal cancer (Weir et al., 2013;
Zackular et al., 2013; Baxter et al., 2014; Wang et al., 2020), multiple sclerosis (Jangi et al., 2016;
Berer et al., 2017; Cekanaviciute et al., 2017; Liu et al., 2019) and Parkinson’s disease (Keshavarzian
et al., 2015; Hill-Burns et al., 2017; Heintz-Buschart et al., 2018).
A number of the human observational studies, which were a mix of quite different approaches,
reported a higher abundance of some bacteria including A. muciniphila in diseased population groups,
but the reverse was also observed. In addition, these studies lacked a longitudinal design and,
therefore, may be subject to reverse causation and other sources of bias.
Transfer of microbiota from diseased population groups or transfer of A. muciniphila to gnotobiotic/
germ-free/transgenic mice (Ganesh et al., 2013; Zackular et al., 2013; Baxter et al., 2014; Asquith
et al., 2016; Desai et al., 2016; Berer et al., 2017; Cekanaviciute et al., 2017; Seregin et al., 2017;
Bian et al., 2019; Liu et al., 2019; Ring et al., 2019; Stoll et al., 2019; Zhai et al., 2019; Ou et al.,
2020; Wang et al., 2020) gave some results, albeit also in different directions, and the relevance of
such studies for humans is questionable.
The Panel notes that associations of A. muciniphila with diseases (neurological, autoimmunity and
other) are inconsistent and that causal relationships have not been established.
Information on antimicrobial resistance (AMR) and potential mobile elements in
A. muciniphila BAA-835
The applicant provided an AMR phenotypic study (Gueimonde, 2019, unpublished) evaluating the
presence of AMR factors in A. muciniphila BAA-835, according to the provisions of the EFSA Guidance on
the characterisation of microorganisms used as feed additives or as production organisms (EFSA FEEDAP
Panel, 2018). A. muciniphila BAA-835 presented high resistance levels to aminoglycosides, vancomycin
and ciprofloxacin. Minimum inhibitory concentrations (MICs) obtained for all antimicrobials tested were
similar among the five Akkermansia muciniphila strains tested by the applicant, showing a similar level of
phenotypic resistance within the species. Other studies show that the species A. muciniphila is intrinsically
resistant to vancomycin (MIC > 64 lg/mL), metronidazole (MIC > 64 lg/mL) and penicillin G (MIC 2.8 lg/
mL) (Derrien et al., 2008; Dubourg et al., 2013; Gomez-Gallego et al., 2016).
Additionally, the applicant carried out an in silico interrogation regarding the presence of AMR
genes by comparing the genome sequence to AMR genes included in CARD and NDARO databases.
According to the applicant, the findings suggest that the strain does not harbour any AMR genes of
concern. A previous in silico genome sequencing analysis (Van Passel et al., 2011) identified some
putative antibiotic resistance genes (two beta-lactamases and one metronidazole resistance gene) in A.
muciniphila BAA-835.
The presence of mobile genetic elements in A. muciniphila BAA-835 was investigated using the
MobileElementFinder database. One insertion sequence, ISAmu1 (Accession: NC_010655), was
identified showing 100% coverage and 100% identity, but is unlikely to contribute to the exchange of
AMR genes. According to Gomez-Gallego et al. (2016), some of the AMR genes present in A.
muciniphila have been acquired through evolution from other commensal bacteria species i.e.
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Bacteroides and Bifidobacterium by horizontal transfer. Guo et al. (2017) described the presence of
three antibiotic resistance genes in A. muciniphila strain GP36, which originated from plasmid
pRSF1010 (8,684 bp) of Salmonella enterica. This indicates that some strains of A. muciniphila might
acquire antibiotic resistance genes through lateral gene transfer (Geerlings et al., 2018).
3.10.2. Toxicological studies
The applicant provided four toxicological studies with the NF (Table 5), three of which were
conducted in compliance with OECD principles of good laboratory practice (GLP) (OECD, 1998) and in
accordance with the respective OECD test guidelines (TG).
Genotoxicity
The applicant provided a bacterial reverse mutation test (Brient, 2019a, unpublished; Druart et al.,
2020) and an in vitro mammalian cell micronucleus test (Brient, 2019b, unpublished; Druart et al.,
2020) that were performed with the NF as a suspension in water.
The Panel notes that the NF did not show any mutagenic activity in the bacterial reverse mutation
test and it was not clastogenic or aneugenic in the in vitro micronucleus test.
The Panel notes that genotoxicity testing should have been performed with suitable extracts and
not with whole bacteria. Especially the bacterial reverse mutation test is not a suitable test for whole
bacteria. However, taking into consideration that A. muciniphila lacks toxicity traits and that the
production process does not raise safety concerns, the Panel considers that further genotoxicity testing
is not required.
Subacute toxicity
A 14-day dose range-finding study in Wistar rats (Crl:WI(Han) strain) was provided (Bracken,
2019a, unpublished). The study was not carried out according to any specific guideline.
In the preliminary phase of the study, three males and three females were administered by gavage
1,500 mg/kg body weight (bw) per day of the NF (9.6 9 1010 TFU/kg bw per day) once daily for 3
days. That phase was immediately followed by a dose range-finding phase, where groups of five males
and five females received 0, 1,125 mg (7.2 9 1010 TFU/kg bw per day) or 1,500 mg (9.6 9 1010 TFU/
kg bw per day) per kg bw per day of the NF once daily for 14 days.
There were no deaths and no test item-related clinical signs. Animals given pasteurised A.
muciniphila showed similar weight gains and ate similar amounts of food as controls. No test item-
related macroscopic or microscopic changes were observed at necropsy. A dose-related decrease in
absolute and relative prostate gland weight (for males) and a dose-related higher absolute and relative
pituitary gland weight for females was observed for rats that received the test item as compared to
controls. In the absence of any histopathological findings, these differences were considered non-
adverse by the study authors. Thus, the highest dose tested (i.e. 9.6 9 1010 TFU/kg bw weight per
day) was considered a suitable high dose for the 90-day study.
Subchronic toxicity
The applicant provided a 90-day repeated dose oral toxicity study with the NF in Wistar rats (Crl:WI
(Han) strain) (Bracken, 2019b, unpublished study report; Druart et al., 2020). The study was
Table 5: List of toxicological studies with the NF








Up to 5,000 lg/plate (in absence and
presence of S9 mix) except for TA98
Brient (2019b,
unpublished)
In vitro mammalian cell
micronucleus test (GLP,
OECD TG 487)
Human lymphocytes Up to 750 lg/mL for 3 h (in the
absence and presence of S9 mix);







Up to 1,500 mg/kg bw per day
(9.6 9 1010 cells/kg bw per day)
Bracken (2019b,
unpublished)
90-day repeated dose oral
toxicity (GLP, OECD TG 408)
Wistar rats
Crl:WI(Han)
Up to 1,500 mg/kg bw per day
(9.6 9 1010 cells/kg bw per day)
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conducted in compliance with the OECD principles of GLP and according to OECD TG 408 (OECD,
2018).
Groups of 10 male and 10 female rats received by gavage 0, 75, 375 or 1,500 mg/kg bw per day
of the NF for at least 90 days. The dosages corresponded to 0, 4.8 9 109, 2.4 9 1010 and 9.6 9 1010
cells (measured as TFU)/kg bw per day. The viable A. muciniphila cell count of the batch of the NF as
tested was < 50 CFU/g of the test item.
One animal (female in the high-dose group) was euthanised on day 24, following a dosing error
(perforated oesophagus). There were no further deaths nor were there any clinical signs observed.
There were no differences across study groups in the neurophysiological and behavioural tests.
Animals that were administered the NF had similar weight increase, feed consumption and water
consumption as control animals.
No statistically significant or biologically relevant differences were observed in blood chemistry or
coagulation parameters between controls and the groups that received the NF.
Dose-related increases in absolute neutrophil count and total white blood cell (WBC) count were
observed in males and were statistically significant in the high-dose group. The increase in total WBC
count was due to the increase in neutrophils and to a dose related, but not statistically significant,
increase in lymphocytes. The Panel notes that the increase in WBC counts was small (i.e. 7.8 9 109/L
vs. 6.1 9 109/L) and that the difference to the control group, even though statistically significant,
might have been a consequence of a rather low WBC count in the control group (6.1 9 109/L) when
compared to historical controls (mean: 9.3 9 109/L; range 5.0–13.7 9 109/L). The Panel therefore
considers that the findings reflect normal biological variation rather than an adverse effect.
Dose-related statistically significant reductions in relative (but not absolute) eosinophils were seen
in males in the low- and mid-dose groups but not in the high-dose group. Statistically significant
increases were observed for triiodothyronine (T3) and thyroxine (T4) in males in the low-dose group
and for T4 in males in addition in the high-dose group, as compared to controls. Thyroid-stimulating
hormone (TSH) was slightly (not statistically significantly) increased in the low-dose group. The
Panel considers that these findings are unrelated to the NF as there was no clear dose response
relationship.
There were no differences in organ weights between control groups and groups that received the
NF. There were also no test item-related macroscopic or microscopic (histopathological) findings.
The Panel considers that the no observed adverse effect level (NOAEL) of this study is the highest
dose tested, i.e. 1,500 mg NF/kg bw per day, corresponding to 9.6 9 1010 cells/kg bw per day.
Other animal studies
The applicant provided three short-term (4–5 weeks) studies on the effect of oral administration of
live or pasteurised A. muciniphila or a purified membrane protein from the bacteria on metabolic
parameters in obese and diabetic C57BL/6J mice (all three studies published by Plovier et al., 2017).
In the three studies, mice (8–10/group) were administered daily for 4–5 weeks live or pasteurised
A. muciniphila grown on mucus-based medium or synthetic medium. The mice were kept on high-fat
diet (60% fat, 20% carbohydrates) or normal diet. In one study, one additional group of mice was
given orally 3 lg/day of the membrane protein Amuc_1100 (estimated to be equivalent to 1.5 9 108
CFU of A. muciniphila).
The study authors reported on a number of findings of A. muciniphila, e.g. body weight, weight
gain, fat mass, adipocytes, insulin resistance, dyslipidaemia, goblet cell density, in obese mice. The
authors found that pasteurisation of A. muciniphila seemed to enhance its effects compared to live
bacteria, presented as beneficial by the authors. Furthermore, the study authors isolated a specific
protein, i.e. Amuc_1100, from the outer membrane of A. muciniphila. According to the publication, this
protein interacts with Toll-like receptor 2, is stable at temperatures used for pasteurisation (analysis
indicated a melting temperature of 70°C) and partly showed similar effects as the bacterium in the
studies presented (Plovier et al., 2017).
3.10.3. Human studies
The applicant provided a randomised, double-blind, 3-arm placebo-controlled exploratory pilot
study with the NF in overweight/obese insulin-resistant subjects (Depommier et al., 2019). According
to the study authors, the main objectives of this study were (1) to evaluate the feasibility, safety and
tolerance of A. muciniphila supplementation, and (2) to explore potential metabolic effects of A.
muciniphila supplementation in humans.
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A total of 40 participants were randomised to receive once daily for 12 weeks either a placebo or
1 9 1010 cells/day of live A. muciniphila or 1 9 1010 cells/day of pasteurised A. muciniphila (i.e. the
NF). The Panel notes that this amount is five times less than what the applicant proposed as
conditions of use for the NF.
Eight subjects dropped out of the study (two in the placebo group, one in the pasteurised bacteria
(NF) group, five in the live bacteria group), resulting in 32 subjects who completed the trial.
This study, even though designed as an efficacy study, included a number of safety-related
endpoints, e.g. systolic and diastolic blood pressure, glycated haemoglobin (HbA1c), blood biochemical
and haematological parameters (including WBC count), C-reactive protein, prothrombin time, plasma
lipopolysaccharides (LPS), glomerular filtration rate, etc. No adverse effects were observed for the
analysed endpoints.
No difference in the frequency of other adverse events (i.e. nausea, flatulence, bloating, cramps,
borborygmi, gastro-oesophageal reflux) between the groups was observed during the study.
The Panel considers that this study does not raise safety concerns. However, the Panel notes the
limitations of the study, i.e. scope (efficacy study), low number of subjects, low dose of the NF, study
population (overweight or obese insulin-resistant subjects), short study duration, limited number of
safety-related endpoints. The Panel thus considers that this exploratory pilot study is of limited value
for the safety assessment of the NF.
3.11. Allergenicity
The Panel notes the protein content of about 30% in the NF and, therefore, the potential of the NF
to elicit allergic reactions.
However, the Panel also notes that A. muciniphila is part of a balanced gut microbiota. No allergies
are expected to be elicited from its protein composition.
The Panel considers that the risk of allergic reactions to the NF for the general population is
expected to be low.
4. Discussion
The NF which is the subject of the application is pasteurised A. muciniphila. It is proposed by the
applicant to be used as food supplement at max. 5 9 1010 cells/day for adults excluding pregnant and
lactating women, and in foods for special medical purposes.
A. muciniphila is a well-characterised non-toxin producing, avirulent microorganism that has been
reported as part of normal gut microbiota. The number of A. muciniphila in the gut is unknown but it
has been reported to be in the range of 1–3% of total number (estimated to be about 3.8 9 1013
(Sender et al., 2016)) of bacteria. A. muciniphila has also been detected in human milk.
In 2020, the BIOHAZ Panel expressed safety concerns and did not recommend A. muciniphila for
inclusion into the QPS list, since the prevalence of A. muciniphila in gut microbiota was found to be
increased in a number of publications reporting on subjects with various neurological diseases. The
Panel reviewed these and further publications which contained information on a potential relationship
of viable A. muciniphila with disease conditions (neurological, autoimmunity and other). The
Panel notes that reported associations of A. muciniphila with disease conditions are inconsistent and
that causal relationships have not been established.
Nevertheless, in order to prevent possible adverse effects on gut barrier integrity and balance of
the microbiota in susceptible people, the Panel considers that the specification parameter for viable A.
muciniphila should be set to < 10 CFU/g (i.e. limit of detection).
A 90-day repeated dose oral toxicity study with the NF was provided. The Panel considers that the no
observed adverse effect level (NOAEL) is the highest dose of total number of cells (viable and non-viable)
tested in this study, i.e. 9.6 9 1010 cells/kg bw per day. By considering this NOAEL and by applying an
uncertainty factor of 200 (10 (interspecies variability) 9 10 (intraspecies variability) 9 2 (subchronic to
chronic study duration)), the Panel derives a safe level of 4.8 9 108 cells/kg bw per day. For the target
population (adults excluding pregnant and lactating women) with a default body weight of 70 kg (EFSA
Scientific Committee, 2012), this corresponds to a total number of 3.4 9 1010 cells/day.
5. Conclusions
The Panel concludes that the NF, pasteurised A. muciniphila, is safe for the target population at
3.4 9 1010 cells/day, provided that the number of viable A. muciniphila is below 10 cells/g NF.
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5.1. Request for protection of proprietary data in accordance with
Article 26 of Regulation (EU) 2015/2283
The Panel could not have reached the conclusion on the safety of the NF under the proposed
conditions of use without the data claimed as proprietary by the applicant, i.e. bacterial reverse
mutation test (Brient, 2019a, unpublished), in vitro micronucleus assay (Brient, 2019b, unpublished),
14-day dose range-finding toxicity study (Bracken, 2019a, unpublished), 90-day toxicity study
(Bracken, 2019b, unpublished), published toxicity data (Druart et al., 2020), flow cytometry validation
(Jensen, 2019, unpublished), antimicrobial resistance study (Gueimonde, 2019, unpublished).
6. Steps taken by EFSA
1) On 19 May 2020, EFSA received a letter from the European Commission with the request for
a scientific opinion on the safety of pasteurised Akkermansia muciniphila Ref. Ares(2020)
2618529.
2) On 19 May 2020, a valid application on pasteurised Akkermansia muciniphila, which was
submitted by A-Mansia Biotech S.A., was made available to EFSA by the European
Commission through the Commission e-submission portal (NF 2019/1366) and the scientific
evaluation was initiated.
3) On 23 September 2020, EFSA requested the applicant to provide additional information to
accompany the application and the scientific evaluation was suspended.
4) On 20 November 2020, additional information was provided by the applicant through the
Commission e-submission portal and the scientific evaluation was restarted.
5) On 15 December 2020, EFSA requested the applicant to provide additional information to
accompany the application and the scientific evaluation was suspended.
6) On 15 January 2021, additional information was provided by the applicant through the
Commission e-submission portal and the scientific evaluation was restarted.
7) On 15 February 2021, EFSA requested the applicant to provide additional information to
accompany the application and the scientific evaluation was suspended.
8) On 30 April 2021, additional information was provided by the applicant through the
Commission e-submission portal and the scientific evaluation was restarted.
9) During its meeting on 7 July 2021, the NDA Panel, having evaluated the data, adopted a
scientific opinion on the safety of pasteurised Akkermansia muciniphila as a NF pursuant to
Regulation (EU) 2015/2283.
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A Akkermansia
ADME absorption, distribution, metabolism and excretion
AMR antimicrobial resistance
ANI average nucleotide identity
ATCC American Type Culture Collection
BIOHAZ EFSA Panel on Biological Hazards
bw body weight
CARD comprehensive antibiotic resistance database
CFU colony forming units
CIP Collection de l’Institut Pasteur
FEEDAP EFSA Panel on Additives and Products or Substances used in Animal Feed
GLP Good Laboratory Practice
GMP Good Manufacturing Practice
HACCP Hazard Analysis Critical Control Points
HbA1c glycated haemoglobin
ICP-MS inductively coupled plasma mass spectrometry
ISO International Organization for Standardization
LoD limit of detection
LoQ limit of quantification
LPS lipopolysaccharides
MIC minimum inhibitory concentration
NCBI National Center for Biotechnology Information
NDA EFSA Panel on Nutrition, Novel Foods and Food Allergens
NDARO national database of antibiotic resistance organisms
ne estimated number
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NOAEL no observed adverse effect level
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